Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that some synthesized 17-oximino-5-androsten-3β-yl esters demonstrated stronger cytotoxicity and antiandrogenic activity against prostate cancer cells than finasteride.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

This study found that compounds 21–23 and 25 exhibited strong 5α-reductase II inhibition in vitro and significantly reduced rat prostate weight, performing comparably to finasteride.

This review examines patents and publications on steroid sulfatase inhibitors since 1999 and reports no new clinical results, highlighting their potential for treating estrogen- and androgen-driven conditions.

The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.